Other key examples are amplification of EGFR (7p11.2) in about 40% of glioblastoma cases [58], ERBB2/HER2 (17q12) in 15–20% of breast cancer cases [59] and MET (7q31) in 1–2% of metastatic colorectal cancer cases [60]. Here, ERBB2 is linked to breast carcinoma.